Galmed Pharmaceuticals News

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

BenzingaJul 24, 2023 08:57 ET

Galmed Pharmaceuticals Analyst Ratings

BenzingaJul 24, 2023 08:56 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Galmed Pharmaceuticals (GLMD) and Rani Therapeutics Holdings (RANI)

TipRanksJan 6, 2023 06:35 ET

Galmed Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow JonesAug 8, 2022 08:19 ET

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5

MT NewswiresAug 8, 2022 06:38 ET

H.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)

TipRanksAug 8, 2022 06:30 ET

Galmed Pharmaceuticals Cut to Hold From Buy by Canaccord Genuity

Dow JonesAug 8, 2022 06:21 ET

Galmed Pharmaceuticals Price Target Cut to $1.00/Share From $5.00 by Canaccord Genuity

Dow JonesAug 8, 2022 06:21 ET

Galmed Pharmaceuticals analyst ratings

Benzinga Analyst RatingsAug 8, 2022 06:14 ET

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Benzinga Real-time NewsAug 8, 2022 06:14 ET

Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5

MT NewswiresAug 4, 2022 15:42 ET